China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

In a welcome step and a move that will potentially benefit millions of Chinese citizens, the Govt of the Peoples Republic of China has announced incremental changes to its erstwhile import and regulatory policy that will allow the easier influx of affordable medicines from overseas.

China relaxes import regulations to improve access and availability of affordable medicines

China's structural reform to its local healthcare system furthers its resolve to progressively drive down drug prices, speed up the approval of new medicines so that they can reach the market quickly, paving the way for greater imports of high-quality medicines.

Welcoming the development as positive and much awaited by Indian and global generic manufacturers, Dr Gurpreet Sandhu, President, Council for Healthcare and Pharma (CHP) said: " We hope the initial reforms to open up the Chinese market by 1 December 2019 for generics in small batches will be further deepened to allow for larger imports, as reforms succeed. I believe, as a result, the Chinese population will benefit through greater access and improved availability of a larger basket of essential and improved medicines, at competitive costs, effectively lowering the cost of medical care in China."

There has been a positive response from patients to China cutting back import tariffs on 28 drugs including the much-required anti-cancer drugs from India, which are in great demand due to their lower prices as compared to imports from the West. China is among the most populous countries in the world with an ageing population and its need for medicine is therefore significant and growing. The potential for generics to support the healthcare needs of China is therefore huge.

There are many complementarities that can be unleashed by the Indian Pharmaceutical industry which is today at a high level of maturity and widely regarded for its technical prowess. India's production costs too are approximately 33% lower than in the West (US) and Indian pharmaceuticals account for nearly 20% of global generic exports by volume. India can thus become a stable and reliable source of supply of medicines to China, which is importantly ranked as the second largest pharmaceutical market in the world.

In addition to its significant capacity, India is among the largest importer of bulk drugs from China, which are then converted into intermediaries and finished dosage forms for export to foreign markets. A few Indian companies have hitherto had joint ventures with their Chinese counterparts, which are now being revived. Further investment is also being made to better service the Chinese market and for export from China.

Recent ventures announced by prominent generic companies in China include the pact between Sun Pharma and CMS, Aurobindo Pharma and Luoxin, Cipla and Jiangsu Acebright besides the introduction of a strategic pipeline of 70 products from Dr Reddy's Laboratories and Cancer drugs by NATCO Pharma. The recently announced merger between US majors Mylan and Upjohn also has significant plans to scale up its combined presence in China.

Read More

Related news

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Exciting new vaccine targets killer disease TB

Exciting new vaccine targets killer disease TB

28 Aug 2019

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings

6 Aug 2019

The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.

Read more 
Mylan and Pfizer create new global pharma company

Mylan and Pfizer create new global pharma company

29 Jul 2019

The transaction will allow the new company to expand the geographic reach of Mylan's existing broad product portfolio and future pipeline.

Read more 
GSK opens new continuous manufacturing facilities in Singapore

GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more